Financhill
Sell
28

XTNT Quote, Financials, Valuation and Earnings

Last price:
$0.51
Seasonality move :
-19.32%
Day range:
$0.48 - $0.51
52-week range:
$0.33 - $1.24
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.55x
P/B ratio:
1.55x
Volume:
3.8K
Avg. volume:
108.9K
1-year change:
-57.89%
Market cap:
$66.8M
Revenue:
$117.3M
EPS (TTM):
-$0.12

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
XTNT
Xtant Medical Holdings
$32.3M -$0.02 9.96% -33.33% $1.75
CATX
Perspective Therapeutics
-- -$0.30 -- -41.72% $15.58
INFU
InfuSystems Holdings
$36.3M $0.05 5.54% -40% $14.13
RVP
Retractable Technologies
-- -- -- -- --
VNRX
VolitionRX
$1M -$0.05 123.53% -51.52% $3.37
VTAK
Catheter Precision
$600K -$0.18 118.75% -11.57% --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
XTNT
Xtant Medical Holdings
$0.48 $1.75 $66.8M -- $0.00 0% 0.55x
CATX
Perspective Therapeutics
$2.59 $15.58 $175.1M -- $0.00 0% 13.99x
INFU
InfuSystems Holdings
$5.55 $14.13 $116.6M 55.50x $0.00 0% 0.89x
RVP
Retractable Technologies
$0.75 -- $22.5M -- $0.00 0% 0.59x
VNRX
VolitionRX
$0.56 $3.37 $52M -- $0.00 0% 36.22x
VTAK
Catheter Precision
$0.38 -- $3.1M 0.44x $0.00 0% 1.03x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
XTNT
Xtant Medical Holdings
44.29% 0.232 55.45% 0.94x
CATX
Perspective Therapeutics
-- -3.661 -- --
INFU
InfuSystems Holdings
29.32% 2.514 13.28% 1.23x
RVP
Retractable Technologies
1.55% -0.326 11.72% 5.80x
VNRX
VolitionRX
-28.76% -0.785 8.83% 0.19x
VTAK
Catheter Precision
12% -2.395 128.21% 0.53x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
XTNT
Xtant Medical Holdings
$16M -$1.9M -21.41% -35.34% -6.38% -$7K
CATX
Perspective Therapeutics
-- -$18.6M -- -- -- -$26.3M
INFU
InfuSystems Holdings
$18.2M $2.6M 2.82% 4.33% 7.76% $2.8M
RVP
Retractable Technologies
-$14.8K -$5.1M -16.57% -16.83% -18.58% -$6.5M
VNRX
VolitionRX
-- -$5.8M -- -- -1217.88% -$5.5M
VTAK
Catheter Precision
$86K -$2.9M -63.93% -65.84% -4258.33% -$2.8M

Xtant Medical Holdings vs. Competitors

  • Which has Higher Returns XTNT or CATX?

    Perspective Therapeutics has a net margin of -10.04% compared to Xtant Medical Holdings's net margin of --. Xtant Medical Holdings's return on equity of -35.34% beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    XTNT
    Xtant Medical Holdings
    50.85% -$0.02 $77.1M
    CATX
    Perspective Therapeutics
    -- -$0.21 --
  • What do Analysts Say About XTNT or CATX?

    Xtant Medical Holdings has a consensus price target of $1.75, signalling upside risk potential of 264.58%. On the other hand Perspective Therapeutics has an analysts' consensus of $15.58 which suggests that it could grow by 501.43%. Given that Perspective Therapeutics has higher upside potential than Xtant Medical Holdings, analysts believe Perspective Therapeutics is more attractive than Xtant Medical Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    XTNT
    Xtant Medical Holdings
    2 0 0
    CATX
    Perspective Therapeutics
    10 1 0
  • Is XTNT or CATX More Risky?

    Xtant Medical Holdings has a beta of 0.413, which suggesting that the stock is 58.747% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.251, suggesting its more volatile than the S&P 500 by 25.149%.

  • Which is a Better Dividend Stock XTNT or CATX?

    Xtant Medical Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xtant Medical Holdings pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios XTNT or CATX?

    Xtant Medical Holdings quarterly revenues are $31.5M, which are larger than Perspective Therapeutics quarterly revenues of --. Xtant Medical Holdings's net income of -$3.2M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, Xtant Medical Holdings's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xtant Medical Holdings is 0.55x versus 13.99x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    XTNT
    Xtant Medical Holdings
    0.55x -- $31.5M -$3.2M
    CATX
    Perspective Therapeutics
    13.99x -- -- -$15.1M
  • Which has Higher Returns XTNT or INFU?

    InfuSystems Holdings has a net margin of -10.04% compared to Xtant Medical Holdings's net margin of 2.76%. Xtant Medical Holdings's return on equity of -35.34% beat InfuSystems Holdings's return on equity of 4.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    XTNT
    Xtant Medical Holdings
    50.85% -$0.02 $77.1M
    INFU
    InfuSystems Holdings
    53.82% $0.04 $81.4M
  • What do Analysts Say About XTNT or INFU?

    Xtant Medical Holdings has a consensus price target of $1.75, signalling upside risk potential of 264.58%. On the other hand InfuSystems Holdings has an analysts' consensus of $14.13 which suggests that it could grow by 154.51%. Given that Xtant Medical Holdings has higher upside potential than InfuSystems Holdings, analysts believe Xtant Medical Holdings is more attractive than InfuSystems Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    XTNT
    Xtant Medical Holdings
    2 0 0
    INFU
    InfuSystems Holdings
    4 0 0
  • Is XTNT or INFU More Risky?

    Xtant Medical Holdings has a beta of 0.413, which suggesting that the stock is 58.747% less volatile than S&P 500. In comparison InfuSystems Holdings has a beta of 1.755, suggesting its more volatile than the S&P 500 by 75.5%.

  • Which is a Better Dividend Stock XTNT or INFU?

    Xtant Medical Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystems Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xtant Medical Holdings pays -- of its earnings as a dividend. InfuSystems Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios XTNT or INFU?

    Xtant Medical Holdings quarterly revenues are $31.5M, which are smaller than InfuSystems Holdings quarterly revenues of $33.8M. Xtant Medical Holdings's net income of -$3.2M is lower than InfuSystems Holdings's net income of $933K. Notably, Xtant Medical Holdings's price-to-earnings ratio is -- while InfuSystems Holdings's PE ratio is 55.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xtant Medical Holdings is 0.55x versus 0.89x for InfuSystems Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    XTNT
    Xtant Medical Holdings
    0.55x -- $31.5M -$3.2M
    INFU
    InfuSystems Holdings
    0.89x 55.50x $33.8M $933K
  • Which has Higher Returns XTNT or RVP?

    Retractable Technologies has a net margin of -10.04% compared to Xtant Medical Holdings's net margin of -18.58%. Xtant Medical Holdings's return on equity of -35.34% beat Retractable Technologies's return on equity of -16.83%.

    Company Gross Margin Earnings Per Share Invested Capital
    XTNT
    Xtant Medical Holdings
    50.85% -$0.02 $77.1M
    RVP
    Retractable Technologies
    -0.14% -$0.07 $84.8M
  • What do Analysts Say About XTNT or RVP?

    Xtant Medical Holdings has a consensus price target of $1.75, signalling upside risk potential of 264.58%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Xtant Medical Holdings has higher upside potential than Retractable Technologies, analysts believe Xtant Medical Holdings is more attractive than Retractable Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    XTNT
    Xtant Medical Holdings
    2 0 0
    RVP
    Retractable Technologies
    0 0 0
  • Is XTNT or RVP More Risky?

    Xtant Medical Holdings has a beta of 0.413, which suggesting that the stock is 58.747% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 2.083, suggesting its more volatile than the S&P 500 by 108.265%.

  • Which is a Better Dividend Stock XTNT or RVP?

    Xtant Medical Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xtant Medical Holdings pays -- of its earnings as a dividend. Retractable Technologies pays out -3.32% of its earnings as a dividend.

  • Which has Better Financial Ratios XTNT or RVP?

    Xtant Medical Holdings quarterly revenues are $31.5M, which are larger than Retractable Technologies quarterly revenues of $10.3M. Xtant Medical Holdings's net income of -$3.2M is lower than Retractable Technologies's net income of -$1.9M. Notably, Xtant Medical Holdings's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xtant Medical Holdings is 0.55x versus 0.59x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    XTNT
    Xtant Medical Holdings
    0.55x -- $31.5M -$3.2M
    RVP
    Retractable Technologies
    0.59x -- $10.3M -$1.9M
  • Which has Higher Returns XTNT or VNRX?

    VolitionRX has a net margin of -10.04% compared to Xtant Medical Holdings's net margin of -1226.82%. Xtant Medical Holdings's return on equity of -35.34% beat VolitionRX's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    XTNT
    Xtant Medical Holdings
    50.85% -$0.02 $77.1M
    VNRX
    VolitionRX
    -- -$0.07 -$17.8M
  • What do Analysts Say About XTNT or VNRX?

    Xtant Medical Holdings has a consensus price target of $1.75, signalling upside risk potential of 264.58%. On the other hand VolitionRX has an analysts' consensus of $3.37 which suggests that it could grow by 501.2%. Given that VolitionRX has higher upside potential than Xtant Medical Holdings, analysts believe VolitionRX is more attractive than Xtant Medical Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    XTNT
    Xtant Medical Holdings
    2 0 0
    VNRX
    VolitionRX
    2 1 0
  • Is XTNT or VNRX More Risky?

    Xtant Medical Holdings has a beta of 0.413, which suggesting that the stock is 58.747% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.092, suggesting its more volatile than the S&P 500 by 9.182%.

  • Which is a Better Dividend Stock XTNT or VNRX?

    Xtant Medical Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xtant Medical Holdings pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios XTNT or VNRX?

    Xtant Medical Holdings quarterly revenues are $31.5M, which are larger than VolitionRX quarterly revenues of $474.5K. Xtant Medical Holdings's net income of -$3.2M is higher than VolitionRX's net income of -$5.8M. Notably, Xtant Medical Holdings's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xtant Medical Holdings is 0.55x versus 36.22x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    XTNT
    Xtant Medical Holdings
    0.55x -- $31.5M -$3.2M
    VNRX
    VolitionRX
    36.22x -- $474.5K -$5.8M
  • Which has Higher Returns XTNT or VTAK?

    Catheter Precision has a net margin of -10.04% compared to Xtant Medical Holdings's net margin of -4291.67%. Xtant Medical Holdings's return on equity of -35.34% beat Catheter Precision's return on equity of -65.84%.

    Company Gross Margin Earnings Per Share Invested Capital
    XTNT
    Xtant Medical Holdings
    50.85% -$0.02 $77.1M
    VTAK
    Catheter Precision
    89.58% -$2.01 $14.6M
  • What do Analysts Say About XTNT or VTAK?

    Xtant Medical Holdings has a consensus price target of $1.75, signalling upside risk potential of 264.58%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 419.62%. Given that Catheter Precision has higher upside potential than Xtant Medical Holdings, analysts believe Catheter Precision is more attractive than Xtant Medical Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    XTNT
    Xtant Medical Holdings
    2 0 0
    VTAK
    Catheter Precision
    0 0 0
  • Is XTNT or VTAK More Risky?

    Xtant Medical Holdings has a beta of 0.413, which suggesting that the stock is 58.747% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.541, suggesting its less volatile than the S&P 500 by 154.132%.

  • Which is a Better Dividend Stock XTNT or VTAK?

    Xtant Medical Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xtant Medical Holdings pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios XTNT or VTAK?

    Xtant Medical Holdings quarterly revenues are $31.5M, which are larger than Catheter Precision quarterly revenues of $96K. Xtant Medical Holdings's net income of -$3.2M is higher than Catheter Precision's net income of -$4.1M. Notably, Xtant Medical Holdings's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xtant Medical Holdings is 0.55x versus 1.03x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    XTNT
    Xtant Medical Holdings
    0.55x -- $31.5M -$3.2M
    VTAK
    Catheter Precision
    1.03x 0.44x $96K -$4.1M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Reddit a Buy on the Dip?
Is Reddit a Buy on the Dip?

Reddit (NYSE:RDDT) share price has been on the proverbial ropes…

Qualcomm Stock: 5G Leader at a Bargain Price?
Qualcomm Stock: 5G Leader at a Bargain Price?

Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…

What Is Buffett Buying and Selling Now?
What Is Buffett Buying and Selling Now?

In Q4 of last year, Warren Buffett made a few…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
59
GRRR alert for Mar 15

Gorilla Technology Group [GRRR] is up 29.72% over the past day.

Sell
49
SMTC alert for Mar 15

Semtech [SMTC] is up 21.28% over the past day.

Buy
62
PLPC alert for Mar 15

Preformed Line Products [PLPC] is up 17.38% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock